Covid vaccine: Eight-week gap seen as sweet spot for Pfizer jab antibodies

Covid vaccine: Eight-week gap seen as sweet spot for Pfizer jab antibodies A longer gap between first and second doses of the Pfizer-BioNTech Covid vaccine makes the body's immune system produce more infection-fighting antibodies, UK researchers have found.

Experts say the findings support the UK's decision on extending dosing intervals from the initial recommendation of three weeks.

An eight-week gap seems to be the sweet spot for tackling the Delta variant. BBC News

See also: 

• Sustained T cell immunity, protection and boosting using extended dosing intervals of BNT162b2 mRNA vaccine (open access preprint) The Pitch Study
• Daily contact testing in schools cuts absences, study finds BBC News
• Covid cases at record levels for 20 to 29-year-olds  BBC News
• Covid: China rejects WHO plan for second phase of virus origin probe  BBC News
• Rapid COVID-19 tests could be as effective as PCR lab tests if enough people get tested The Daily Mail
• Covid UK: NHS symptom-tracking app's data U-turns and estimates 60,000 people are still falling ill The Daily Mail
• Covid pass could be compulsory for entry to large events in England – video The Guardian